Capivasertib
Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1, Akt2 and Akt3, respectively.
Product Specifications
CAS Number
1143532-39-1
Product Name Alternative
AZD5363
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; Autophagy
Type
Reference compound
Related Pathways
Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AZD5363.html
Purity
99.96
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO
Molecular Formula
C21H25ClN6O2
Molecular Weight
428.92
Precautions
H302, H315, H319, H335
References & Citations
[1]Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11 (4) :873-87.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Akt1; Akt2; Akt3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
P4258-17G-ML750 100 µL
Platelet Derived Growth Factor BB (PDGF-BB, Platelet-derived Growth Factor B Chain, Platelet-derived Growth Factor beta, Platelet-derived Growth Factor beta Polypeptide, PDGFB, PDGF-B, PDGF-B Chain, Becaplermin, C-sis, FLJ12858, Oncogene SIS, PDGFB/COL1A1 Fusion Gene, Platelet-derived Growth Factor 2, PDGF2, PDGF-2, Simian Sarcoma Viral (v-sis) Oncogene Homolog, SSV, SIS, V-sis Platelet-derived Growth Factor beta Polypeptide) (MaxLight 750) discontinued
Sign In for Pricing
View Details 